Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Miscellaneous >

InMed Pharmaceuticals Inc. (IMLFF)

Add IMLFF Price Alert      Hide Sticky   Hide Intro
Moderator: lesgetrich, NetworkNewsWire
Search This Board: 
Last Post: 7/21/2017 12:51:56 PM - Followers: 153 - Board type: Free - Posts Today: 0

A drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids

InMed Pharmaceuticals, Inc. (OTCQB: (IMLFF; CSE: IN) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company's cannabinoid biosynthesis technology and drug development pipeline, serves as InMed's fundamental value driver.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents while developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of $1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

Investment Highlights

  • Extensive portfolio of assets in dermatology, ocular disease and additional indications and cannabinoid biosynthesis
    Positioned to achieve value-driving, near-term corporate milestones with limited investment
    Led by a management team of experienced professionals capable of building value in biopharmaceuticals



Bioinformatics: a significant promise for future drug discovery

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis.

With this tool, InMed aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases.

After discovering active cannabinoids, InMed tests and confirms their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company's proprietary biosynthesis process of cannabinoid manufacturing will be most promising.

InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.



InMed is building a robust product pipeline through its proprietary discovery platform and research & product development programs. The company continues to seek innovative product candidates for the treatment in following therapeutic areas:

  • Ocular Diseases
    Pain & Inflammation
  • CNS
    Respiratory Disease
    Metabolic Disease

InMed's pipeline currently includes two drug candidates in preclinical development: INM-750 for the treatment of epidermolysis bullosa (EB); and INM-085 for the treatment of glaucoma.


Referred to as "The Worst Disease You've Never Heard Of," EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. Through the development of INM-750, InMed is attempting to address this significant unmet medical need, for which there is no approved treatment or cure. INM-750 replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

Market Potential - Amicus Therapeutics recently acquired Scioderm, Inc. and its lead EB drug candidate, Zorblisa™, for $847 million. Notably, Scioderm's sole clinical asset was Zorblisa.

JP Morgan and Cowen Research Reports estimate that peak sales for Zorblisa could reach $900 million to $1.2 billion.


INM-085 is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure.

Market Potential - The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease. Worldwide, glaucoma represents a market of $5.6 billion.


The Case for Cannabinoids

The majority of pharmaceutical and academic research & development activities being performed with cannabis revolves around the understanding of its biologically active ingredients, the cannabinoids.

Currently there are 90+ cannabinoids that have been isolated from cannabis, each affecting the body's cannabinoid receptors and responsible for unique pharmacological effects. There are currently two known types of cannabinoid receptors, called CB1 and CB2.

CB1 receptors are primarily found in the brain and central nervous system, and to a lesser extent in other issues..

CB2 receptors are mostly in the peripheral organs, especially cells associated with the immune system.

Cannabinoids can be administered by smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Once in the body, most cannabinoids are metabolized in the liver, although some is stored in fat.

Cannabinoids can be separated from the plant by extraction with organic solvents. However, to produce high purity, cannabinoid chemical synthesis or semisynthesis is generally required.

InMed specializes in developing novel therapies through the R&D into the extensive pharmacology of cannabinoids in combination with innovative drug delivery systems, positioning the company as a unique first-mover in the cannabis-pharma sector.



InMed's management team has well over a century of combined experience in the biopharmaceutical space. Together, the professionals comprising this team are guiding InMed into exciting opportunities in the cannabis-pharma sector.

Eric A. Adams, President & CEO
Eric Adams is a seasoned biopharmaceutical executive with over 25 years of experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.

He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana aerospace industry, most recently with Metal Form, Inc., a privately held aerospace manufacturing company, where he served as president and CEO from 1987 to September of 1999.

Dr. Sazzad Hossain, Ph.D., M.Sc., Chief Scientific Officer
Dr. Sazzad Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.

Dr. Ado Muhammed, MD, DPM, MFPM, Chief Medical Officer
Dr. Ado Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs. His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role and others at GW Pharmaceuticals, Dr. Muhammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. Dr. Muhammed's received his MD at Ahmadu Bello University followed by an MSc in Orthopaedics at University College London. Dr. Muhammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff followed by an MBA in Business Administration at the University of Leicester. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.

Alexandra D.J. Mancini, M.Sc., Senior Vice President, Clinical and Regulatory Affairs
Alexandra Mancini has over 30 years' of global biopharmaceutical R&D experience with a particular emphasis on clinical development and regulatory affairs. Ms. Mancini has been an executive with several biotech companies, overseeing a wide range of drug development activities. As Sr. VP of Clinical & Regulatory Affairs at Sirius Genomics, her role included identifying and managing external resources for medical expertise in sepsis; clinical data management; and statistical theory, programming and analyses. While at INEX Pharmaceuticals as Sr. VP of Clinical & Regulatory Affairs, Ms. Mancini oversaw Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance for oncology. She served as VP of Regulatory Affairs at QLT Inc. for oncology and ocular diseases, playing a significant role in the development of VISUDYNER from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Ms. Mancini also led the regulatory approval process for the anticancer drug PHOTOFRINR and its associated medical devices, the first drug-device combination product approved by the US Food and Drug Administration. Ms. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions. Ms. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.

Chris Bogart, SVP, Corporate Strategy & Investor Relations
Chris Bogart is a co-founder of InMed Pharmaceuticals and currently serves as the SVP of Corporate Strategy and Investor Relations. Mr. Bogart has over 18 years in international business development, strategic decision-making and planning. Mr. Bogart is a seasoned capital markets professional with an extensive background in equity financings and strategic communications for publicly traded companies in a senior management role. He has planned, executed and maintained Investor Relations & Communication initiatives in Canada, United States and Europe.

Jeff Charpentier, CFO, Chief Financial Officer
Jeff Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.


InMed Pharmaceuticals, Inc.
#350-409 Granville Street
Vancouver, BC
Canada V6C 1T2
Phone: (604) 669-7207

1324 Lexington Ave.
Suite 117
New York, NY 10128
Phone: (212) 418-1217


NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website:



InMed Pharmaceuticals is a drug discovery and development company uniquely
focused on the therapeutic potential of cannabinoids.



InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

Corporate Presentation



InMed Pharmaceuticals is currently developing two products in its drug pipeline: INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma.


Epidermolysis Bullosa (EB) is group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily from friction or trauma. Internal organs and bodily systems can also be affected by EB. It is a result in a defect of anchoring between the dermis and epidermis cause most frequently by the absence of certain keratins (or, proteins) in the skin. EB is an orphan disease with no currently approved treatments and has a significant unmet medical need. INM-750 will potentially be the first therapy designed and developed specifically to modulate disease activity and to alleviate symptoms in EB.

INM-750 includes multiple cannabinoids as the active ingredients:

The cannabinoids included in INM-750 were selected to modulate keratin levels in patients with EB with the expectation of having a disease modulating effect
A secondary consideration in selection of the cannabinoids was addressing symptoms of EB such as inflammation, wound healing, skin regeneration, itching, and pain
INM-750 is being developed for topical application, designed to maximize penetration of the cannabinoids to the epidermal / dermal junction in the skin.



Glaucoma is a group of eye disorders which result in damage of the optic nerve. The damage is most often caused by an abnormally high pressure in the eye and is one of the leading causes of blindness in the developed world.

INM-085 will be the first ever glaucoma treatment developed that is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. The cannabinoids in INM-085 have been selected to reduce the elevated intra-ocular pressure (IOP) in the affected eyes and provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues.

INM-085 is designed as a topical formulation to be administered directly to the eye. The formulation that has been designed by InMed is a proprietary polymer-based formulation to facilitate absorption of the cannabinoids into the eye while also being well tolerated by the patients. We envision a once-a-day application, at bedtime, to deliver effective dose levels of INM-085.



Bioinformatics: Proprietary Drug / Disease Targeting Tool

InMed’s has developed a computer-based program to assist in the identification of novel cannabinoids using: (i) comprehensive algorithms to integrate data from numerous bioinformatics databases, (ii) a database on the structure of currently approved pharmaceutical products, and (iii) an extensive database on over 90 individual cannabinoid drugs found in cannabis.

InMed’s data included in its bioinformatics assessment tool are derived from both public and propriety based sources, and include information on:
Protein-Protein interactions
Gene Regulation
Epigenetic modification
Cell signal networks, and

InMed uses processes called “random walk algorithms” and “guilt by association” to establish gene and protein-protein interaction networks to identify multi-target based approaches for therapy development for specific diseases.By using its comprehensive pharmaceutical and cannabinoid structures database, and by creating associations between approved pharmaceuticals (whose pharmacodynamics effects are well characterized) and cannabinoids with similar structures, InMed identifies active cannabinoids to act on above mentioned genes and proteins.Once a series of potentially active cannabinoids are identified for a specific disease target, InMed will test and confirm their activity in biological systems with 
in vitro and in vivo
 experimentation.This type of bioinformatics assessment, as a general approach, represents significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.



Proposed Targets to Develop Drugs From Cannabis and Other Botanical Sources


Epidermolysis Bullosa
Pachyonychia Congenital
Epidermolytic Ichthyosis
Pemphigus Vulgaris


Ocular Allergies

Pain and Inflammation

Orofacial Pain
Rheumatoid Arthritis


Huntington’s Disease





Metabolic Disease


Metabolic Syndrome


University of British Columbia
Department of Chemical & Biological Engineering
Vancouver Campus
2360 East Mall
Vancouver, BC Canada V6T 1Z3

Department of Pharmaceutical Sciences
Vancouver Campus
2405 Westbrook Mall
Vancouver, BC, Canada V6T 1Z3

University of Debrecen
Research Center for Molecular Medicine, Department of Physiology
1H-4032 Debrecen, Nagyerdei krt. 98





Cap Structure (as of Tue Jan, 1, 2017)
Issued & Outstanding 93.1 Million
Warrants 14.1 Million
Options 14.7 Million
Fully-Diluted 121.9 Million
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IMLFF News: Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth 03/15/2017 09:30:00 AM
IMLFF News: InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex 03/02/2017 09:00:00 AM
IMLFF News: InMed Engages Peter Mountford as Strategic Advisor 05/05/2015 04:00:00 AM
IMLFF News: InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S. 04/30/2015 11:00:00 AM
IMLFF News: InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy 04/15/2015 06:00:00 AM
#1259  Sticky Note Interview with InMed CEO Eric Adams on company goals lesgetrich 12/22/16 10:57:01 PM
#2987   Looks like someone wants out today. greenwillow 07/21/17 12:51:56 PM
#2986   Their she goes...need to get Volume up. greenwillow 07/17/17 03:45:11 PM
#2985   Looks like IMLFF wants to make a move higher. greenwillow 07/14/17 10:41:36 AM
#2984   Been watching imlff for a while waiting for Smittytnt 07/12/17 12:12:45 AM
#2983   Great another promo starkd748 07/11/17 12:04:10 PM
#2982   IMLFF Enters Research and Development Collaboration with ATERA SAS NetworkNewsWire 07/10/17 09:17:35 AM
#2981   InMed Signs R&D Agreement with ATERA GetRichorGetHighTryn 07/10/17 07:32:27 AM
#2980   no worries here. sometimes the path to GetRichorGetHighTryn 07/09/17 09:59:56 PM
#2979   I'm not a huge fan of the paid greenwillow 07/05/17 11:25:31 PM
#2978   The more I see these pump releases the Vinpat 07/05/17 04:58:53 PM
#2977   IMLFF Focused on the Science of Cannabinoids NetworkNewsWire 07/05/17 01:06:01 PM
#2976   This is a long term investment. It takes lesgetrich 06/29/17 09:09:16 AM
#2975   Whats going on here ? Game over ? Wilddieb2 06/29/17 02:07:58 AM
#2973   IMLFF Targeting Blockbuster Therapeutics NetworkNewsWire 06/26/17 02:56:00 PM
#2972   Good plan! Matilda1 06/23/17 11:40:17 PM
#2971   1. Rub some marijuana on your EB GetRichorGetHighTryn 06/23/17 11:06:42 AM
#2970   IMLFF Takes Additional Step toward Clinical Trials for INM-750 NetworkNewsWire 06/22/17 03:44:23 PM
#2969   Yes, the sizable investment was encouraging and impressive. greenwillow 06/22/17 09:22:31 AM
#2968   They did raise $5 million which is pretty Vinpat 06/21/17 10:53:54 PM
#2967   If it's as effective as they claim it greenwillow 06/21/17 08:57:25 PM
#2966   I don't know what to think. I'm skeptical Vinpat 06/21/17 08:18:37 PM
#2965   Agreed. What do you think about their greenwillow 06/21/17 04:48:19 PM
#2964   Management needs to save its money for R&D. Vinpat 06/21/17 03:04:34 PM
#2963   IMLFF is a Player in the Billion Dollar NetworkNewsWire 06/20/17 03:55:33 PM
#2962   IMLFF Gains Attention for Its Operational Developments and NetworkNewsWire 06/19/17 02:45:01 PM
#2960   More like 50 cents! jons245 06/17/17 08:15:33 PM
#2959   LOL! Dream on jons245 06/17/17 08:14:54 PM
#2958   Going to $5.oo this summer. See you shortorlong 06/17/17 09:25:45 AM
#2957   You mean crash jons245 06/16/17 04:13:09 PM
#2956   Lots of time to accumulate before the DFresh1 06/15/17 07:34:57 AM
#2954   In agreement regarding strength of partnership with Revive, greenwillow 06/13/17 09:56:28 PM
#2953   Guess I've been invested in this stock a Matilda1 06/13/17 09:08:17 PM
#2952   I can't figure you out. Not sure if AntonChigurh 06/13/17 07:02:33 PM
#2951   A "Luke-warm" news release, followed by the DumpTards Matilda1 06/13/17 01:55:03 PM
#2950   Interesting you mention the deal expired a long greenwillow 06/13/17 01:31:50 PM
#2949   I still watch IMLFF because of their EB AntonChigurh 06/13/17 01:08:50 PM
#2948   That expired a while ago. Haven't heard since. AntonChigurh 06/13/17 01:07:21 PM
#2947   This will take at least a year to develop. Vinpat 06/13/17 12:12:21 PM
#2946   One of many deals expected. We know greenwillow 06/13/17 09:16:20 AM
#2945   IMLFF Teams with Pharmaseed to Advance Development of INM-750 NetworkNewsWire 06/13/17 09:04:08 AM
#2944   InMed Announces Agreement to Advance a Topical Formulation rosie10 06/13/17 08:55:05 AM
#2943   is uncanny the word..the timing of chart and news Mandofellow 06/13/17 08:40:47 AM
#2942   Such a great management team that failure is George Green 06/12/17 11:30:20 AM
#2941   Options exercised @.45 = $517 000.00 on top Matilda1 06/11/17 10:11:53 PM
#2940   I'm curious when some of these deals/partnerships will greenwillow 06/10/17 11:39:36 PM
#2939   Thanks... I made some calls and figured it Matilda1 06/10/17 10:27:10 PM
#2938   Nevertheless, a bunch of big new investors bought lesgetrich 06/10/17 09:51:41 PM
#2937   Honestly, I wouldn't be giving much credit to AntonChigurh 06/10/17 01:33:53 PM
#2936   The brokerages that handled the $5.7 million public lesgetrich 06/10/17 08:58:40 AM
#2935   probably gonna head back down on monday anyways.....20 George Green 06/09/17 02:31:32 PM